杜邦公司发布2025年财报，业绩超预期并上调2026年指引

Core Insights - DuPont Company reported a solid financial performance for Q4 2025 and the full year, providing an optimistic outlook for 2026, which was positively received by the market [1] Financial Performance - In Q4 2025, the company achieved net sales of $1.7 billion, remaining flat year-over-year; adjusted earnings per share (EPS) were $0.46, up 18% year-over-year, exceeding market expectations [2] - For the full year 2025, net sales reached $6.8 billion, a 2% increase year-over-year; adjusted EPS was $1.68, reflecting a 16% year-over-year growth [2] - Operating cash flow for the year was $1.412 billion, with free cash flow amounting to $1.079 billion [2] Business Developments - Growth drivers included healthcare and water treatment technologies, with healthcare solutions experiencing high single-digit organic growth due to demand in medical packaging and biopharmaceuticals [3] - Water treatment solutions showed strong performance in industrial and municipal sectors, achieving mid-single-digit growth [3] - Diversified industrial solutions benefited from growth in the aerospace market, while construction solutions faced a decline due to a weak construction market, resulting in mid-single-digit organic sales decline [3] Strategic Initiatives - The company completed the spin-off of its electronics business, focusing on core areas such as healthcare and water treatment [4] - Under the new structure, DuPont announced a $2 billion stock buyback authorization and initiated its first dividend distribution [4] - The company expects adjusted EPS for 2026 to be in the range of $2.25 to $2.30, above market expectations; net sales guidance is set at $7.08 to $7.14 billion, also exceeding expectations [4] Stock Performance - Following the earnings report, the stock closed at $51.63 on February 11, 2026, with a single-day increase of 4.45%; however, it retraced to $49.42 the next day, reflecting a 4.09% decline, yet the year-to-date cumulative increase stands at 22.94% [5] Analyst Opinions - Morgan Stanley raised its target price from $44 to $52 post-earnings report, acknowledging the growth potential following the company's spin-off [6]